Drug intelligence / Profile preview

anti-influenza A immune plasma

Development stage
Approved
Lead developer
National Institute of Allergy and Infectious Diseases
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Influenza A plasma, specifically anti-influenza A immune plasma, is a blood-derived biologic product obtained from donors who have high levels of antibodies against the influenza A virus due to prior infection or vaccination. This convalescent or immune plasma is intended for use as a passive immunotherapy to treat patients with severe influenza A infections. The therapeutic effect is mediated by the transfer of polyclonal antibodies that neutralize the virus, primarily by binding to surface proteins like hemagglutinin, thereby preventing viral attachment and entry into host cells. It is being investigated as a potential treatment to reduce complications and mortality in patients where standard antiviral treatments may be insufficient or where viral resistance is a concern.

Other names
Influenza A plasmahigh titer influenza A plasmaanti-influenza A immune plasma collection
02

Targets

M2e (Influenza A matrix protein 2 ectodomain)NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on anti-influenza A immune plasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-influenza A immune plasma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call